Geraldine Harriman

Geraldine C. Bussolaria Harriman is a chemist and biotech entrepreneur with leadership roles in multiple scientific companies.

Geraldine C. B. Harriman, Ph.D.
NationalityAmerican
Alma materUniversity of Rhode Island, University of Kansas

Education

Harriman received a B.S. degree in chemistry from American International College. She studied Biomedical and Pharmaceutical Sciences with Prof. Elie Abushanab at the University of Rhode Island, receiving her doctorate in 1991. Harriman completed postdoctoral studies with Prof. Gunda Georg[1] at the University of Kansas, focusing on the medicinal chemistry of paclitaxel analogs.[2]

Career

Harriman's first industrial position was at the immunology start-up LeukoSite,[3] which was acquired by Millennium Pharmaceuticals in 1999.[4] Over the next seven years, Harriman rose to become the Head of Chemistry at Millennium, when she was recruited by Galenea in 2007. She served as VP and Head of Chemistry there until 2010, when she was appointed VP at Nimbus Therapeutics, formed by Atlas Ventures in 2009. Nimbus specialized in computational and outsourced drug discovery. The program Harriman oversaw - "Nimbus Apollo" - focused on targeting the acetyl-coA carboxylase pathway to treat fatty liver diseases such as Non-Alcoholic Steatohepatitis (NASH). Gilead acquired Nimbus Apollo for US$1.2 billion in 2016.[5]

In 2017, Harriman co-founded Atlas-backed HotSpot Therapeutics, which will seek for allosteric inhibitors to potentially treat autoimmune and metabolic disorders. Harriman is a co-inventor on over twenty small-molecule use patents and 30 scientific publications.[6]

Awards
  • 2017 - NEVY Award "Exit of the Year" for Nimbus Apollo[7]
  • 1993 - Marion Merrill Dow Scientific Education Partnership Postdoctoral Fellow, University of Kansas[8]

References
  1. "Alumni - Georg Research Group". sites.google.com. Retrieved 2018-10-24.
  2. Georg, Gunda I.; Harriman, Geraldine C. B.; Vander Velde, David G.; Boge, Thomas C.; Cheruvallath, Zacharia S.; Datta, Apurba; Hepperle, Michael; Park, Haeil; Himes, Richard H. (1994-12-07), "Medicinal Chemistry of Paclitaxel", ACS Symposium Series, American Chemical Society, pp. 217–232, doi:10.1021/bk-1995-0583.ch016, ISBN 978-0841230736
  3. "Team - HotSpot Therapeutics". HotSpot Therapeutics. Retrieved 2018-10-24.
  4. "Millennium Set To Buy Leukosite". Retrieved 2018-10-24.
  5. Booth, Bruce. "Atlas-Backed Nimbus Delivers Its Apollo Mission: A $1.2B Gilead Partnership". Forbes. Retrieved 2018-10-24.
  6. "Crunchbase Profile: Geraldine Harriman". CrunchBase. October 2018.
  7. "The 2017 NEVY Awards Recap: Winners & Pictures". VentureFizz. 2017-05-18. Retrieved 2018-10-24.
  8. Georg, Gunda I.; Cheruvallath, Zacharia S.; Harriman, Geraldine C.B.; Hepperle, Michael; Park, Haeil (1993-11-01). "An efficient semisynthesis of taxol from (3R,4S)-N-Benzoyl-3-[(t-butyldimethylsilyl)oxy]-4-phenyl-2-azetidinone and 7-(Triethylsilyl)baccatin III". Bioorganic & Medicinal Chemistry Letters. 3 (11): 2467–2470. doi:10.1016/S0960-894X(01)80979-3. ISSN 0960-894X.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.